MEDICUS PHARMA LTD. Proceeds from Convertible Debt
MEDICUS PHARMA LTD. (MDCX) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-03-25
- MEDICUS PHARMA LTD. proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00.
- MEDICUS PHARMA LTD. proceeds from convertible debt for the quarter ending 2025-09-30 was $0.00.
- MEDICUS PHARMA LTD. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00.
- MEDICUS PHARMA LTD. proceeds from convertible debt for the quarter ending 2024-09-30 was $0.00.
- MEDICUS PHARMA LTD. proceeds from convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- MEDICUS PHARMA LTD. proceeds from convertible debt for fiscal 2024 was $5.17M, a 934.50% increase from fiscal 2023.
- MEDICUS PHARMA LTD. proceeds from convertible debt for fiscal 2023 was $500.00K.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $5.17M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.17M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $5.17M 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $500.00K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |